Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Nathan, D, Buse, J, Davidson, M, Ferrannini, E, Holman, R, Sherwin, R, Zinman, B
التنسيق:	Journal article
اللغة:	English
منشور في:	2008

Management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones (Diabetologia DOI: 10.1007/s00125-007-0873-z)
حسب: Nathan, D, وآخرون
منشور في: (2008)

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
حسب: Nathan, D, وآخرون
منشور في: (2008)

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
حسب: Nathan, D, وآخرون
منشور في: (2009)

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy (vol 49, pg 2816, 2006)
حسب: Nathan, D, وآخرون
منشور في: (2006)

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
حسب: Nathan, D, وآخرون
منشور في: (2006)

Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
حسب: Nathan, D, وآخرون
منشور في: (2009)

Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
حسب: Nathan, D, وآخرون
منشور في: (2009)

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
حسب: Nathan, D, وآخرون
منشور في: (2009)

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
حسب: Nathan, D, وآخرون
منشور في: (2006)

Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus
حسب: Yenny Yenny
منشور في: (2016-04-01)

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
حسب: Punthakee, Z, وآخرون
منشور في: (2012)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
حسب: Rosaria Vincenza Giglio, وآخرون
منشور في: (2022-10-01)

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
حسب: John M Stafford, وآخرون
منشور في: (2007-10-01)

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
حسب: N Waugh, وآخرون
منشور في: (2010-09-01)

Thiazolidinedione, friend or foe?
حسب: Sachan A
منشور في: (2016-04-01)

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
حسب: Shoko Horita, وآخرون
منشور في: (2015-01-01)

Implications of Postprandial Hyperglycaemia and Role of Voglibose in Type 2 Diabetes Mellitus
حسب: S R Pattanaik, وآخرون
منشور في: (2018-04-01)

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
حسب: Inzucchi, SE, وآخرون
منشور في: (2012)

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
حسب: Inzucchi, SE, وآخرون
منشور في: (2012)

Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus
حسب: Houyu Zhao, وآخرون
منشور في: (2022-10-01)

Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
حسب: Inzucchi, SE, وآخرون
منشور في: (2012)

Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.
حسب: Gloyn, A, وآخرون
منشور في: (2009)

Managing post stroke hyperglycaemia: moderate glycaemic control is better? An update
حسب: Wan Sulaiman, Wan Aliaa, وآخرون
منشور في: (2014)

Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
حسب: Shibib L, وآخرون
منشور في: (2024-08-01)

Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones
حسب: D. Alemán-González-Duhart, وآخرون
منشور في: (2016-01-01)

Perioperative hyperglycaemia
حسب: B.M. Gardner
منشور في: (2012-06-01)

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (vol 55, pg 1577, 2012)
حسب: Inzucchi, SE, وآخرون
منشور في: (2013)

The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus
حسب: Shaw, J, وآخرون
منشور في: (1999)

The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus.
حسب: Shaw, J, وآخرون
منشور في: (1999)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
حسب: Elis Susilawati, وآخرون
منشور في: (2023-08-01)

Therapeutic Actions of the Thiazolidinediones in Alzheimer’s Disease
حسب: María José Pérez, وآخرون
منشور في: (2015-01-01)

Challenges in drug discovery for thiazolidinedione substitute
حسب: Jian-ping Ye
منشور في: (2011-10-01)

Glucocorticoid induced hyperglycaemia
حسب: M I Weerakkody, وآخرون
منشور في: (2012-05-01)

The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats
حسب: Derya Köseoğlu, وآخرون
منشور في: (2021-03-01)

Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
حسب: Taylor, C, وآخرون
منشور في: (2009)

Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)
حسب: Pascal Froment, وآخرون
منشور في: (2006-01-01)

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
حسب: Wei Wei, وآخرون
منشور في: (2011-01-01)

Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
حسب: Eun-Hee Cho
منشور في: (2022-11-01)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
حسب: Chang Ho Ahn, وآخرون
منشور في: (2019-05-01)

Biological potential of thiazolidinedione derivatives of synthetic origin
حسب: Sucheta, وآخرون
منشور في: (2017-12-01)

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

مواد مشابهة

مواد مشابهة